Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure.

[1]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[2]  E. Braunwald,et al.  Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. , 1995, Journal of the American College of Cardiology.

[3]  K. Dickstein,et al.  Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. , 1995, The American journal of cardiology.

[4]  K. Dickstein,et al.  Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. , 1995, British heart journal.

[5]  N. Christensen,et al.  Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. , 1995, Journal of cardiac failure.

[6]  M. Costanzo,et al.  Candidate evaluation and selection for heart transplantation , 1995, Current opinion in cardiology.

[7]  C. Hall,et al.  In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. , 1995, Circulation.

[8]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[9]  S. Snapinn,et al.  The plasma concentration of N‐terminal proatrial natriuretic factor anf (1‐98) is related to prognosis in severe heart failure , 1994, Clinical cardiology.

[10]  G. Francis.  Determinants of prognosis in patients with heart failure. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  R. T. Lie,et al.  Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. , 1993, British heart journal.

[12]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[13]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[14]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[15]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[16]  P. Mathisen,et al.  Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. , 1993, Scandinavian journal of clinical and laboratory investigation.

[17]  Kaye Mp.  The Registry of the International Society for Heart and Lung Transplantation: tenth official report--1993. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  S. Wassertheil-Smoller,et al.  Prognosis in ischemic heart disease. Can you tell as much at the bedside as in the nuclear laboratory? , 1992, Archives of internal medicine.

[19]  M. Landsman,et al.  Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. , 1992, The American journal of cardiology.

[20]  R. Rodeheffer,et al.  Prognostic features in patients with congestive heart failure and selection criteria for cardiac transplantation. , 1992, Mayo Clinic proceedings.

[21]  J Keegan,et al.  Predictors of prognosis in severe chronic heart failure. , 1992, American heart journal.

[22]  G. Lamas,et al.  Activation of neurohumoral systems following acute myocardial infarction. , 1991, The American journal of cardiology.

[23]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[24]  M. Capelli,et al.  Plasma atrial natriuretic factor in patients with acute myocardial infarction. , 1990, European heart journal.

[25]  W. Stevenson,et al.  Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. , 1989, Circulation.

[26]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[27]  M. Kinoshita,et al.  Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. , 1989, American heart journal.

[28]  K. Nakao,et al.  γ-Atrial natriuretic polypeptide (γANP)-derived peptides in human plasma: Cosecretion of N-terminal γANP fragment and αANP , 1988 .

[29]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[30]  R. Zimmerman,et al.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. , 1988, Circulation research.

[31]  H. Matsubara,et al.  The role of atrial pressure in secreting atrial natriuretic polypeptides. , 1987, American heart journal.

[32]  M. Packer.  How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. , 1987, Journal of the American College of Cardiology.

[33]  N. Seidah,et al.  The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. , 1987, The Biochemical journal.

[34]  P. Erne,et al.  Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. , 1986, The New England journal of medicine.

[35]  S. Ball,et al.  Plasma alpha natriuretic peptide in cardiac impairment. , 1986, British medical journal.

[36]  E. Bates,et al.  The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. , 1986, Circulation.

[37]  P. Yock,et al.  Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. , 1984, Circulation.

[38]  L. Horowitz,et al.  Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. , 1983, Journal of the American College of Cardiology.

[39]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.